The US drug giant beat Novo Nordisk in the $10 bln battle for biotech Metsera with the help of the Federal Trade Commission.

U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera , capping a fierce biotech bidding ...

Pfizer has agreed to acquire Metsera for $10 billion, outbidding Novo Nordisk in a heated competition. Metsera's board ...

Pfizer has won a $10 billion deal to acquire obesity drug developer Metsera, securing foothold in lucrative weight-loss ...

On Monday, 10 November 2025, the healthcare world was abuzz as two pharmaceutical giants, Pfizer and Novo Nordisk, fiercely ...

Pfizer has fended off Nova Nordisk for control of the next-gen weight-loss drug developer Metsera. Meanwhile, Resmed watches ...

Pfizer has secured a $10 billion acquisition of obesity drug developer Metsera, outbidding rival Novo Nordisk in a heated ...

Metsera, the US biotech with a pipeline of next-generation metabolic hormone weight loss drugs, has agreed a sale to Pfizer ...

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...

Pfizer Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...

The founders of Metsera have a battle to buy their company. It would be their second time striking deal gold.